NCT04893083终止不适用
A Multi-center, Non-interventional Phase 0 Study for the Collection of Biospecimens From Patients With Parkinson's Disease.
Neuron23 Inc.8 个研究点 分布在 4 个国家目标入组 65 人开始时间: 2021年6月28日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 终止
- 发起方
- 入组人数
- 65
- 试验地点
- 8
- 主要终点
- Genetic Marker
研究概览
简要总结
This study aims to collect, analyze and preserve biospecimens from patients with or without LRRK2-associated Parkinson's Disease for the purpose of discovering and developing new treatments and novel biomarkers.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Male or female ≥40
- •Clinical diagnosis of Parkinson's disease meeting United Kingdom Brain Bank criteria and modified Hoehn and Yahr Stage I, II, or III;
- •Willing to undergo genetic testing for neurologic genotyping panel; -If being treated for Parkinson's disease, must have been on a stable dose of anti- Parkinson's disease medications for a minimum of 30 days prior to Day 1;
- •If taking statins, fibrates, antipsychotic or anticonvulsant medications at Day 1, must have been on a stable dose for a minimum of 30 days, and are not likely to require a change in dosage for the remainder of the study;
排除标准
- •Any major medical illness or unstable medical condition within 6 months of screening that, in the opinion of the Investigator or Sponsor, may interfere with the subject's ability to comply with study procedures or abide by study restrictions.
- •Diagnosis of a significant central nervous system disease other than Parkinson's disease(eg, Huntington's disease, frontotemporal dementia, multi-infarct dementia, normal pressure hydrocephalus, multiple system atrophy, progressive supranuclear palsy, drug- induced parkinsonism, Alzheimer's disease)
- •History of stroke;
- •History of epilepsy or seizure disorder other than febrile seizures as a child, or any seizure or unexpected loss of consciousness (eg, syncope) within 6 months prior to Day 1;
- •History of traumatic brain injury with residual neurological deficit; -If taking anti-Parkinson's disease medication(s)and are likely to require a change in anti- Parkinson's disease medication(s) during the study;
- •Known active infectious disease or active infections within 30 days prior to Day 1;
- •Any vaccination within 21 days prior to Day 1;
- •Currently taking, or planning to take, anti-coagulant medications or antiplatelet medications during the study;
- •Allergy to Lidocaine (xylocaine) or its derivatives or any other LP contraindications;
- •Any other condition which could interfere with, or the treatment for which might interfere with, the conduct of the study or which would, in the opinion of the Investigator, unacceptably increase the subject's risk by participating in the study; -Any systemic glucocorticoids taken within 14 days prior to Day 1 or non-steroidal anti- inflammatory drugs taken within 4 days prior to Day 1;
- •Received blood products within 30 days prior to Day 1;
- •Donated blood within 30 days prior to Day 1.
结局指标
主要结局
Genetic Marker
时间窗: 1 day
Test for LRRK2 mutations in Parkinson disease patients; identifying patients with potential genetic modifiers
次要结局
未报告次要终点
研究者
研究点 (8)
Loading locations...
相似试验
Unknown
不适用
LRRK2 G2385R Leucocyte and Urine Biomarker StudyParkinson DiseaseNCT04436848University of Malaya150
已完成
不适用
Fox BioNet Project: LRRK2-002Parkinson DiseaseNCT03545425Michael J. Fox Foundation for Parkinson's Research114
已完成
不适用
FoxBioNet: ECV (Extracellular Vesicle) 004Parkinson DiseaseNCT04603326Michael J. Fox Foundation for Parkinson's Research140
已完成
2 期
Stem Cell Monitoring for CML Patients Undergoing Nilotinib TherapyChronic Myeloid LeukemiaNCT02353728Weill Medical College of Cornell University16
终止
2 期
Study to Identify Biomarkers of Clinical Response to Aflibercept in Patients With Metastatic Colorectal CancerMetastatic Colorectal CancerNCT02045030CR-CSSS Champlain-Charles-Le Moyne14